KNTE
Income statement / Annual
Last year (2023), Kinnate Biopharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Kinnate Biopharma Inc.'s net income was -$112.65 M.
See Kinnate Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$799,000.00 |
$604,000.00 |
$123,000.00 |
$83,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$799,000.00 |
-$604,000.00 |
-$123,000.00 |
-$83,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$90.77 M
|
$88.15 M
|
$67.17 M
|
$29.24 M
|
$8.96 M
|
$5.68 M
|
| General & Administrative
Expenses |
$0.00
|
$30.37 M
|
$22.95 M
|
$6.76 M
|
$3.06 M
|
$1.96 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$27.44 M
|
$30.37 M
|
$22.95 M
|
$6.76 M
|
$3.06 M
|
$1.96 M
|
| Other Expenses |
$0.00 |
$2.25 M |
$348,000.00 |
-$5,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$118.21 M |
$118.52 M |
$90.11 M |
$36.00 M |
$12.01 M |
$7.63 M |
| Cost And Expenses |
$119.01 M |
$118.52 M |
$90.11 M |
$36.00 M |
$12.01 M |
$7.63 M |
| Interest Income |
$8.53 M |
$0.00 |
$348,000.00 |
$245,000.00 |
$43,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$799,000.00
|
$604,000.00
|
$123,000.00
|
$83,000.00
|
$171,860.00
|
$161,141.00
|
| EBITDA |
-$118.21 M
|
-$117.92 M
|
-$89.99 M
|
-$35.92 M
|
-$12.01 M
|
-$7.63 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.36 M
|
$2.25 M
|
$348,000.00
|
$240,000.00
|
$43,000.00
|
$0.00
|
| Income Before Tax |
-$112.65 M |
-$116.27 M |
-$89.76 M |
-$35.76 M |
-$11.97 M |
-$7.63 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.25 M |
-$348,000.00 |
-$328,000.00 |
-$43,000.00 |
$0.00 |
| Net Income |
-$112.65 M |
-$114.02 M |
-$89.42 M |
-$35.43 M |
-$11.93 M |
-$7.63 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.42 |
-2.59 |
-2.05 |
-0.81 |
-0.28 |
-0.71 |
| EPS Diluted |
-2.42 |
-2.59 |
-2.05 |
-0.81 |
-0.28 |
-0.71 |
| Weighted Average Shares
Out |
$46.58 M
|
$44.07 M
|
$43.60 M
|
$43.48 M
|
$43.33 M
|
$10.80 M
|
| Weighted Average Shares
Out Diluted |
$46.58 M
|
$44.07 M
|
$43.60 M
|
$43.48 M
|
$43.33 M
|
$10.80 M
|
| Link |
|
|
|
|
|
|
